Seizure Disorders

Marinus has completed a proof of concept Phase 2 clinical trial in refractory adult partial onset seizures. This trial demonstrated a statistically significant reduction in seizure frequency as compared to placebo patients. Ganaxolone has been shown to be safe and well tolerated with chronic use in both refractory adult and pediatric patients.

Posttraumatic Stress Disorder

A clinical trial to investigate the safety and efficacy in PTSD patients has started recently. This study is being conducted by the INTRuST consortium and is funded by the Dept. of Defense. Results of this trial are expected in 2012. For more information please visit www.clinicaltrials.gov

Fragile-X Syndrome

A group of neurologists at the University of California, Davis has recently been awarded a grant to study ganaxolone for the treatment of Fragile-X. This study is planned to start later in 2011.

To learn more about these clinical trial and for future studies of ganaxolone, please visit www.clinicaltrials.gov and search with keyword: MARINUS, you can also contact us at clinicaltrials@marinuspharma.com.